Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
A minimalist illustration of a test tube with bubbles, symbolizing drug discovery.

May 4, 2026

Big Tech Targets Drug Discovery with Wave of Life Science Platforms

Big tech companies are increasingly focusing on drug discovery, leveraging advanced AI and cloud platforms to streamline research and development processes.Nvidia's CEO, Jensen Huang, emphasizes that the future of accelerated computing lies in application acceleration rather than just hardware. This is particularly relevant in drug discovery, where lengthy approval processes and high clinical trial failure rates present significant challenges. To address these issues, major players like Amazon W
Silhouette of a human tonsil organoid

May 2, 2026

ALP Bio Raises €1.9M to Advance Immune Organoid AI Platform

ALP Bio AG has successfully raised €1.9 million in pre-seed funding to enhance its innovative immune organoid AI platform aimed at addressing immunogenicity risks in drug development.The funding round, led by Munich-based 42CAP with contributions from Venture Kick and angel investors, marks a significant step for the Swiss biotech startup founded in 2025. ALP Bio's platform uniquely integrates human tonsil organoid biology with generative AI to identify and mitigate the formation of anti-drug an
A minimalist representation of a drug compound in a dark palette.

May 2, 2026

OpenAI GPT-Rosalind: Specialized Life Sciences AI for Faster Drug Discovery Research

OpenAI has introduced GPT-Rosalind, a specialized AI model aimed at enhancing drug discovery efforts in the life sciences sector. This advanced tool is designed to assist researchers by leveraging deep scientific reasoning to navigate the complexities of biology and drug development, particularly within regulated environments.GPT-Rosalind operates under a controlled research preview, limiting access to qualified scientific users in regulated laboratory settings. Its primary focus is on translati
A minimalist illustration of a pill symbolizing drug discovery.

May 1, 2026

AI Tools Life Sciences Companies Are Using

Artificial Intelligence (AI) is increasingly embedded in the life sciences sector, influencing various stages from drug discovery to clinical research and manufacturing.The integration of AI tools in life sciences is transforming operations across the pharmaceutical value chain. Approximately 80% of professionals in this field utilize AI in drug discovery, with a significant majority of executives anticipating that intelligent automation will greatly impact the industry in the coming years. Comp
A minimalist representation of a small molecule in flat design.

Apr 29, 2026

Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Glob

Lantern Pharma has transformed its predictBBB.ai platform into a Large Quantitative Model (LQM), enhancing its capabilities for precision molecular intelligence in drug development. This new real-time engine is now accessible globally through a web interface, allowing researchers to obtain comprehensive analyses of small molecules with unprecedented speed and efficiency.The evolution of predictBBB.ai from a blood-brain barrier permeability predictor to a robust LQM signifies a major advancement
A flat illustration of a DNA strand and recombinase enzyme

Apr 29, 2026

Profluent & Eli Lilly Inks a Deal Worth $2.25 Bn to Develop AI-Designed Recombinases for Genetic Medicine

Profluent has partnered with Eli Lilly in a significant collaboration worth up to $2.25 billion to develop AI-designed recombinases aimed at advancing genetic medicine.This strategic alliance combines Profluent’s AI-driven protein design capabilities with Eli Lilly’s established expertise in clinical and drug development. The goal is to enhance programmable gene editing therapeutics, enabling more precise and scalable DNA editing solutions that traditional methods struggle to achieve.The partner
A minimalist illustration of a DNA helix and circuit board

Apr 28, 2026

Why AI maker Anthropic’s deal with Coefficient Bio could be a pharma turning point

The recent acquisition of Coefficient Bio by Anthropic for $400 million marks a significant shift in the intersection of AI and drug development, highlighting the increasing trend of collaboration between AI firms and the pharmaceutical industry.This acquisition stands out not only due to its substantial price tag but also because Coefficient Bio is a relatively nascent startup with only a handful of employees and an undisclosed technology platform. The founders bring substantial experience from
A protein model in a dimly lit lab, showcasing molecular structure.

Apr 28, 2026

Fathom Therapeutics: $47 Million Series A Raised To Advance AI And Physics-Based Drug Design Platform

Fathom Therapeutics has successfully secured $47 million in a Series A funding round to enhance its innovative drug discovery platform that leverages artificial intelligence and physics.This financing round, led by Sutter Hill Ventures and supported by notable investors like Chemistry and Alexandria Venture Investments, aims to propel the development of Fathom's AI-powered platform, Microcosmos. This proprietary engine simulates protein dynamics at an atomic level, offering a more accurate depic
A flat illustration of a patent document with a checkmark, representing approval in drug discovery.

Apr 28, 2026

Patent Analysis Is Increasingly Shaping AI-driven Target And Drug Candidate Selection - Healthcare - Isle of Sark

The integration of artificial intelligence (AI) in drug discovery is revolutionizing the identification of therapeutic targets and candidates, yet it introduces complexities in resource allocation for these inventions.Recent insights from a review by Pun et al. in *Nature Reviews Drug Discovery* highlight how AI enhances target identification through innovative techniques like multi-omics integration and knowledge graphs. This expansion necessitates a new framework that incorporates not only tra
A minimalist illustration of a pill symbolizing drug discovery in biotech.

Apr 27, 2026

Korean Biotech Firms Forge 'AI Alliances' to Discover Next-Generation Drugs

Korean biotech companies are increasingly forming alliances focused on AI-driven drug discovery, aiming to enhance the efficiency and success rates of developing new therapeutics.One notable partnership is between HK inno.N and Atommerce, which was announced recently. This collaboration targets the development of innovative treatments for obesity, specifically seeking to identify new drug candidates that do not rely on the existing GLP-1 (incretin) therapies. By leveraging Atommerce's advanced A
Petri dish with cultured cells in a dimly lit lab

Apr 27, 2026

German drugmaker launches AI research centre in London

Boehringer Ingelheim is set to enhance its research capabilities by establishing a new AI and machine learning centre in London, aimed at revolutionizing drug discovery.The facility, located in the Knowledge Quarter at King’s Cross, will concentrate on the integration of AI into human biology, facilitating the development of targeted therapies. This initiative is part of a broader strategy to utilize AI and machine learning to expedite the identification and modeling of biological processes crit
Flat design of a small molecule and protein silhouette

Apr 27, 2026

Fathom Therapeutics, Formerly Atommap, Raises $47 Million in Oversubscribed Series A Financing to Translate Physics and AI-Enabled Small Molecule Design into Next-Generation Medicines

Fathom Therapeutics, previously known as Atommap, has successfully raised $47 million in an oversubscribed Series A funding round, aimed at enhancing its innovative drug design capabilities through quantum chemistry and AI technologies.Led by Sutter Hill Ventures, this financing round also saw participation from several other prominent investors. Fathom's proprietary platform, Microcosmos, leverages advanced algorithms to simulate protein dynamics at an unprecedented scale, facilitating the desi